2026· Medical Data Mining· Vol 9, pp. 28· 0 citations· 24 references
TL;DR
CDH1 and NISCH promoter methylation in blood-derived cfDNA highlights the innovation of non-invasive approach alternative to tissue biopsy, with potential to complement existing screening modalities such as low-dose CT by improving molecular level detection and reducing false-positive rates.
Abstract
Background: DNA methylation is an epigenetic phenomenon in which DNA methyltransferases (DNMTs) add methyl groups at CpG islands of gene promoter regions, and abnormalities in methylation alter gene expression without changing the DNA sequence. The CDH1 and NISCH genes encode tumor suppressor proteins whose promoter hypermethylation has been implicated in lung carcinogenesis. Blood-derived circulating cell-free DNA (cfDNA) offers a minimally invasive substrate for detecting such epigenetic alterations. Methods: Blood samples were collected from 40 newly diagnosed lung cancer patients (24 NSCLC, 16 SCLC) and 40 age matched healthy controls after ethical approval (IEC: 140th ECM 2A/P5). cfDNA was extracted from plasma, bisulfite-converted, and analyzed for CDH1 and NISCH promoter methylation using methylation-specific PCR (MSP). Statistical analysis was performed using the chi-square test (GraphPad Prism 5.0; P < 0.05). Results: CDH1 and NISCH promoter methylation frequencies in lung cancer patients were 50% and 47.5%, respectively, compared to 22.5% and 35% in healthy controls. No significant association were identified between CDH1 and NISCH promoter methylation and evaluated demographic characteristics of lung cancer patients. CDH1 represented moderate diagnostic performance AUC ≈ 0.64 with higher specificity (77.5%). Conclusion: CDH1 and NISCH promoter methylation in blood-derived cfDNA highlights the innovation of non-invasive approach alternative to tissue biopsy, with potential to complement existing screening modalities such as low-dose CT by improving molecular level detection and reducing false-positive rates. However, larger scale validation required before clinical translation.
Background Plasma cell-free DNA (cfDNA) methylation has emerged as a promising non-invasive approach for cancer detection; however, methylation biomarkers for thyroid carcinoma (THCA) remain insufficiently defined. This study aimed to identify THCA-associated DNA methylation alterations and evaluate their potential dia...
Wei Wu, Ye Wang, Ying Qu et al.· Translational Cancer Researc...· 0 citations
Purpose Aberrant promoter DNA methylation represents an early molecular alteration in oral carcinogenesis and has emerged as a potential source of molecular biomarkers for oral cancer. Although RNF152 has been implicated in cancer-related molecular dysregulation, its promoter methylation and expression status have not...
Madona Gjona, Seval Turna, Comert Sen et al.· Frontiers in Oncology· 0 citations
Long non-coding RNAs (lncRNAs) regulate multiple cellular processes and are involved in the development and progression of human cancers, including renal cell carcinoma (RCC). Genome-wide DNA methylation profiling using Illumina EPIC arrays was performed to identify differentially methylated regions (DMR) associated wi...
Pouriya Faraj Tabrizi, Inga M. Schimansky, Inga Peters et al.· Clinical Epigenetics· 0 citations
Background: Conventional colorectal cancer (CRC) screening methods are hindered by invasiveness and insufficient accuracy, emphasizing the need for noninvasive biomarkers. DNA methylation alterations occur early in tumor development, and hypomethylation of the IGF2 DMR0 region disrupts normal imprinting, leading to IGF...
Screening for gastric cancer (GC) is critical for improving patient survival, yet current clinical methods suffer from invasiveness and limited sensitivity. The aim of this study is to develop a machine learning model for the non-invasive diagnosis of GC using the whole-genome methylation profile of circulating free DN...
Hai-Ling Ou, J. Miao, Fu-Sheng Ling et al.· PLoS Genetics· 0 citations
It is found that methylation was associated with poor prognosis in multiple myeloma and a trend toward reduced overall survival in the CDH1 methylated and MEG3 unmethylated patient groups suggested that CDH1 promoter hypermethylation and MEG3 promoter unmethylation status may predict poor MM prognoses.
S. Yamashita, T. Tachita, K. Kamata et al.· International journal of hem...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.